Graphene Investments SAS Sells 9,500 Shares of Jazz Pharmaceuticals PLC $JAZZ

Graphene Investments SAS trimmed its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 35.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 17,300 shares of the specialty pharmaceutical company’s stock after selling 9,500 shares during the quarter. Graphene Investments SAS’s holdings in Jazz Pharmaceuticals were worth $2,941,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Vestal Point Capital LP acquired a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $127,344,000. Goldentree Asset Management LP acquired a new stake in Jazz Pharmaceuticals during the third quarter worth approximately $149,597,000. Schonfeld Strategic Advisors LLC grew its stake in Jazz Pharmaceuticals by 592.1% during the third quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock worth $57,523,000 after purchasing an additional 373,383 shares during the period. AQR Capital Management LLC boosted its holdings in Jazz Pharmaceuticals by 62.1% in the second quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock worth $84,341,000 after acquiring an additional 304,463 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Jazz Pharmaceuticals by 11.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after acquiring an additional 298,815 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,287 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the transaction, the chief accounting officer directly owned 6,512 shares of the company’s stock, valued at approximately $1,191,305.28. This trade represents a 16.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Norbert G. Riedel sold 3,415 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $192.00, for a total value of $655,680.00. Following the completion of the transaction, the director directly owned 7,024 shares in the company, valued at approximately $1,348,608. This represents a 32.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 74,015 shares of company stock worth $14,180,486. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Trading Up 2.8%

JAZZ opened at $203.42 on Friday. The business has a 50 day simple moving average of $183.52 and a two-hundred day simple moving average of $166.84. The firm has a market capitalization of $12.52 billion, a price-to-earnings ratio of -34.07, a PEG ratio of 0.34 and a beta of 0.23. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. Jazz Pharmaceuticals PLC has a one year low of $97.50 and a one year high of $204.13.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.51 EPS. Analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analysts Set New Price Targets

JAZZ has been the topic of a number of recent research reports. Piper Sandler raised their target price on Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a report on Thursday, March 19th. Wells Fargo & Company boosted their target price on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Royal Bank Of Canada boosted their target price on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Bank of America lifted their price target on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, Truist Financial upgraded Jazz Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $216.21.

Get Our Latest Research Report on Jazz Pharmaceuticals

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

Featured Articles

• Five stocks we like better than Jazz Pharmaceuticals

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).